CSI Market
Sign In | Register

Avalo Therapeutics Inc (AVTX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access AVTX Annual Cash Flow →
The table below presents a historical view of Avalo Therapeutics Inc's cash flow activity, supporting analysis of liquidity trends over time.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
3 Months 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Operating Activities
Income-19.63
Depreciation & amortization0.02
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation3.58
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Non Cash Expense Related To Issuance Of Warrants-
Amortization Of Inventory Fair Value Adjustment-
Impairment Of Intangible Assets Excluding Goodwill-
Equity Securities Fv Ni Unrealized Gain Loss-
Increase Decrease In License Obligation Noncurrent-
Equity Securities Fv Ni Gain Loss-
Disposal Group Including Discontinued Operation Change In Fair Value Of Guarantee-
Contract With Customer Receivable Credit Loss Expense Reversal-
Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Gain Loss Included In Earnings-
Increase Decrease In Lease Incentives-
Change In Fair Value Of Derivative Liability-
Acquired In Process Research And Development-
Fair Value Adjustment Of Derivative Liability-0.48
Transaction Costs From Private Placement-
Increase Decrease In Lease Liability-0.03
Gain Loss On Termination Of Lease-
Income taxes0.01
Losses/ -gains on Investments net0.00
Increase (Decrease) in Other Accounts Payable and Accrued Liabilities-1.50
Increase (Decrease) in Accounts Payable0.22
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.23
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.11
Discontinued operations0.00
Net Cash flow from Operating Activities-17.69
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Proceeds from Sale, Maturity and Collection of Short-term Investments25.51
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Acquired From Asset Acquistion-
Cash Acquired From Asset Acquisition-
Payments For Asset Acquisitions-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities25.51
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock2.18
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-16.88
Payment Of Fractional Shares Upon Conversion Of Preferred Stock To Common Stock-
Payments Of Stock Issuance Costs Excluding Amounts Paid To Underwriters-
Proceeds From Option Or Warrant Exercises-
Proceeds From Registered Direct Offering-
Proceeds From Issuance Of Common Stock And Warrants-
Proceeds From Venture Debt Financing Agreement-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents16.11
Noncash Payment Tax Withholding Share Based Payment Arrangement-
Issuance Of Common Stock And Series C Preferred Stock Pursuant To Acquisition-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.40
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-17.69
Total Cash Flow9.21
4 historic quarters locked

Sign in to unlock the full Avalo Therapeutics Inc cash flow history.

Sign In Create Free Account

About Avalo Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001534120-26-000049

Figures are derived from filed reports and may be restated. Historical data is subject to revision.